Trial Profile
A Long-Term Non-Interventional Postmarketing Study to Assess Safety and Effectiveness of HUMIRA (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 29 Jun 2023
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary) ; Azathioprine; Mercaptopurine
- Indications Ulcerative colitis
- Focus Adverse reactions
- Sponsors AbbVie
- 24 Jan 2022 Planned primary completion date changed from 6 Apr 2027 to 24 Jun 2030.
- 06 Jan 2021 Planned primary completion date changed from 24 Jun 2030 to 6 Apr 2027.
- 09 Jul 2020 Planned End Date changed from 6 Apr 2027 to 24 Jun 2030.